AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
AstraZeneca(AZN) stock is priced at $182.88, giving the company a market capitalization of 286.04B. It carries a P/E multiple of 25.93 and pays a dividend yield of 1.73%.
On 2026-11-17, AstraZeneca(AZN) stock traded between a low of $183.86 and a high of $187.65. Shares are currently priced at $182.88, which is -0.5% above the low and -2.5% below the high.
AstraZeneca(AZN) shares are trading with a volume of 1.61M, against a daily average of 2.73M.
During the past year, AstraZeneca(AZN) stock moved between $153.41 at its lowest and $212.71 at its peak.
During the past year, AstraZeneca(AZN) stock moved between $153.41 at its lowest and $212.71 at its peak.
AZN News
LBT Innovations Limited ( (AU:CC5) ) has shared an announcement. Clever Culture Systems supplies APAS automated culture-plate reading technology for pharmaceut...
...
Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies...
Analyst ratings
90%
of 10 ratingsMore AZN News
Alexion and AstraZeneca (AZN) Rare Disease’s Klygefa has been approved in the European Union, EU, as an add-on to standard therapy for the treatment of generali...
AstraZeneca ( (GB:AZN) ) has issued an announcement. The FDA approved AstraZeneca’s Imfinzi (durvalumab) with neoadjuvant enfortumab vedotin, followed by Imfin...
The latest update is out from AstraZeneca ( (GB:AZN) ). Alexion, AstraZeneca Rare Disease’s Klygefa has received EU approval as an add-on to standard therapy f...
Summit Therapeutics said Sunday that the Food and Drug Administration didn't approve a China-developed drug to treat lung cancer, citing insufficient evidence t...
AstraZeneca’s (AZN) imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by imfinzi monotherapy as adjuvant treatment after ra...
AstraZeneca eliminates 600 respiratory and immunology sales reps: Bloomberg Nov 13, 2026, 2:51 PM ET AstraZeneca PLC (AZN) Stock By : Jonathan Block, SA News Ed...
The Food and Drug Administration said it approved AstraZeneca’s (AZN) Imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.